Oligodendrocytes In Multiple System Atrophy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about the cell type. See the content below for detailed information.
Multiple system atrophy (MSA) is characterized by oligodendroglial alpha-synuclein inclusions called glial cytoplasmic inclusions (GCIs). These inclusions are the hallmark pathology and drive demyelination and neurodegeneration in this oligodendropathy.
- Alpha-synuclein - Phosphorylated (Ser129)
- Ubiquitin - Post-translational modification
- P62 - Sequestosome
- Tubulin - Cytoskeletal elements
- Shape: Wavy, crescent-shaped
- Location: Perinuclear cytoplasm
- Size: Variable (2-10 μm)
- Distribution: Throughout white matter
- Primary oligodendropathy - Direct target
- Myelin loss - Diffuse white matter changes
- Layer splitting - Vacuolation
- Remyelination failure - Oligodendrocyte loss
- GCIs appear before neuronal loss
- Most abundant pathology
- Spatial pattern matches symptoms
- Animal models support oligodendrocyte origin
- Putamen - Caudate > Putamen
- Pontocerebellar pathways - Brainstem
- Cerebellar white matter - Ataxia correlation
- Basal ganglia - Movement symptoms
| Region |
MSA |
PSP |
PD |
| Striatum |
Severe |
Moderate |
Mild |
| Brainstem |
Severe |
Severe |
Mild |
| Cerebellum |
Severe |
Mild |
None |
| Cortex |
Mild |
Moderate |
None |
- Mechanism: Unknown trigger
- Propagation: Cell-to-cell spread
- Strain: Distinct from PD/DLB
- Oligomerization: Early toxic species
- Impaired myelin maintenance
- Metabolic stress
- Calcium dysregulation
- Oxidative damage
- Cerebellar ataxia - Gait instability
- Parkinsonism - Bradykinesia, rigidity
- Autonomic failure - Orthostatic hypotension
- Parkinsonism predominant
- Poor levodopa response
- Rapid progression
- Sleep disorder - REM behavior disorder
- Respiratory dysfunction - Stridor
- Cognitive impairment - Executive dysfunction
- Symptomatic - Levodopa (limited benefit)
- Autonomic - Midodrine, fludrocortisone
- Supportive - Physical therapy
- α-Synuclein immunotherapy - Active/passive vaccines
- Aggregation inhibitors - Small molecules
- Oligodendrocyte protection - Neurotrophic factors
The study of Oligodendrocytes In Multiple System Atrophy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Fanciulli A, Wenning GK (2015). Multiple system atrophy. New England Journal of Medicine.
- Wakabayashi K, et al. (1998). Glial cytoplasmic inclusions in MSA. Acta Neuropathologica.
- Jellinger KA (2014). Neuropathology of MSA. Handbook of Clinical Neurology.